The Concentration of Serum Transforming Growth Factor Beta-1 (TGF-β1) Is Decreased in Cervical Carcinoma Patients

• Published in: Cancer investigation Vol. 20; no. 1; pp. 55 - 59
• Main Authors: Wu, Hwa-Shyi, Li, Ywan Feng, Chou, Chuan-I, Yuan, Chiou Chung, Hung, Mei Whey, Tsai, Lai Chen
• Format: Journal Article
• Language: English
• Published: New York, NY Informa UK Ltd 2002; Taylor & Francis; Informa Healthcare
• Subjects: Biological and medical sciences; Carcinoma, Squamous Cell - blood; Cell Differentiation; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Middle Aged; Transforming Growth Factor beta - blood; Transforming Growth Factor beta1; Tumors; Uterine Cervical Neoplasms - blood; Human; Squamous cell carcinoma; Premalignant lesion; Female; Serum; Uterine cervix; Transforming growth factor β1; Malignant tumor; Epithelium; Carcinogenesis; Uterine cervix diseases; Female genital diseases
• ISSN: 0735-7907; 1532-4192
• DOI: 10.1081/CNV-120000366

Transforming growth factor beta-1 (TGF-β1) is a multifunctional growth factor and known to inhibit the proliferation of epithelial cell. The relationship between serum TGF-β1 level and the presence of cervical cancer was investigated in this study. The patients with cervical squamous cell carcinoma (SCC) had significantly lower level of serum TGF-β1 (39.14±9.03 ng mL; mean ± SD) than those with myoma (49.17±9.38 ng mL) and normal subjects (49.13±8.81 ng mL), (p<0.007 and p<0.001, respectively). TGF-β1 level was also lower in the patients with cervical intraepithelial neoplasia (CIN3) (42.07±9.38 ng mL) than in normal controls (49.13±8.81 ng mL) (p<0.04). It suggested that diminution of the production of TGF-β1 has close association with the neoplastic transformation of cervical epithelium.